Breaking the Efficacy Ceiling in IBD and Beyond

Despite significant advances in treating inflammatory bowel disease (IBD) and other autoimmune conditions, many patients still fail to achieve lasting remission. In this Applied Clinical Trials podcast conversation, Kori Wallace, MD, PhD, vice president and global head of immunology clinical development at AbbVie, examines the biological complexity behind this persistent “efficacy ceiling” and the strategies being explored to move beyond incremental gains. 

Speaking with Mike Christel, group managing editor, MJH Life Sciences, Wallace discusses the shift toward more stringent, tissue-based treatment targets; the potential of combining complementary mechanisms; and the ongoing search for biomarkers that can make precision medicine practical in immunology. She also explores the promise of B-cell depletion and in vivo CAR-T approaches designed to reset the immune system, potentially opening a path toward deep, durable drug-free remission.